- Report
- May 2023
- 81 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Book
- April 2019
- 191 Pages
- Report
- January 2023
- 250 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- September 2022
- 141 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- April 2022
- 189 Pages
Global
From €3402EUR$3,565USD£2,851GBP
- Report
- December 2021
- 280 Pages
Global
From €3543EUR$3,712USD£2,968GBP
- Report
- November 2021
- 181 Pages
Global
From €3543EUR$3,712USD£2,968GBP
- Book
- April 2024
- 1280 Pages
- Book
- August 2022
- 496 Pages
- Book
- March 2020
- 560 Pages
Global
- Book
- August 2018
- 376 Pages
- Book
- August 2018
- 1524 Pages
- Book
- May 2016
- 240 Pages
- Book
- April 2015
- 384 Pages
- Book
- April 2014
- 744 Pages
- Book
- January 2013
- 304 Pages
- Book
- October 2011
- 360 Pages
Europe

The Neurological Disorder market is a subset of the Neurology field, which focuses on the diagnosis and treatment of disorders of the nervous system. This includes conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and stroke. The market is composed of a variety of stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions.
The market is driven by the increasing prevalence of neurological disorders, as well as advances in technology and treatments. Pharmaceutical companies are developing new drugs to treat neurological disorders, while medical device manufacturers are creating innovative products to improve patient care. Healthcare providers are also playing an important role in providing diagnosis and treatment services.
Some companies in the Neurological Disorder market include AbbVie, Biogen, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more